



- 1/4 -

Figure 1: X-ray powder diffractogram of the crystalline compound 2-{2-[[[4-methoxy-2,6-dimethylphenyl)sulphonyl]-(methyl)amino]ethoxy}-*N*-methyl-*N*-[(1*R*,3*S*)-3-(4-methylpiperazin-1-yl)cyclohexyl]acetamide-dihydrochloride (**1**)



- 2/4 -

Figure 2: X-ray powder diffractogram of the crystalline compound 2-{2-[[[4-methoxy-2,6-dimethylphenyl)sulphonyl]-(methyl)amino]ethoxy}-*N*-methyl-*N*-[(1*S*,3*R*)-3-(4-methylpiperazin-1-yl)cyclohexyl]acetamide-dihydrochloride (**2**)



- 3/4 -

Figure 3: X-ray powder diffractogram of the crystalline compound 2-{2-[[4-methoxy-2,6-dimethylphenyl)sulphonyl]-(methyl)amino]ethoxy}-*N*-methyl-*N*-[(1*S*,3*R*)-3-(4-methylpiperazin-1-yl)cyclohexyl]acetamide-(*L*)-tartrate (**3**)




Figure 4: X-ray powder diffractogram of the crystalline compound 2-{2-[[4-methoxy-2,6-dimethylphenyl)sulphonyl]-(methyl)amino]ethoxy}-*N*-methyl-*N*-[(1*R*,3*S*)-3-(4-methylpiperazin-1-yl)cyclohexyl]acetamide-(*D*)-tartrate (**4**)

